| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 1, 2019Attain Stability(TM) Quad MRI SureScan(TM) Lead Designed for Precise Placement and Stability
DUBLIN - May 1, 2019 - Medtronic plc (NYSE:MDT) announced it has received U.S. Food and Drug Administration (FDA) approval for the Attain Stability(TM) Quad MRI SureScan(TM) left heart lead....
-
Feb 20, 2019With Official Launch and First Implant, Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication
DUBLIN - February 20, 2019 - Medtronic plc (NYSE:MDT) today announced both the U.S. launch of Deep Brain Stimulation (DBS) for medically-refractory epilepsy and the first commercially implanted...
-
Feb 7, 2019Approval Based on Clinical Data from the PREMIER Trial - New Indication Provides Options for Patients with Small or Medium, Wide-Necked Brain Aneurysms
DUBLIN - February 7, 2019 - Medtronic plc (NYSE:MDT) announced today that it has received U.S. Food and Drug Administration (FDA) approval on an expanded indication for its Pipeline(TM) Flex...
-
Sep 13, 2018
(GLOBE NEWSWIRE via COMTEX) --Company Marks its Eleventh Consecutive Year on the North American Dow Jones Sustainability Index (DJSI) DUBLIN - September 13, 2018 - Medtronic plc (NYSE:MDT) was...
-
Jun 13, 2018FDA Approved, DBS Clinician Programmer Optimizes the Programming Experience By Addressing Day-to-Day Clinical Management Challenges
DUBLIN - June 13, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) recently approved its state-of-the art...
-
May 1, 2018Medtronic Receives FDA Approval for Deep Brain Stimulation Therapy for Medically Refractory Epilepsy7-Year Data from the SANTE Trial Showed Median Seizure Frequency Reduction of 75 percent in Patients with Drug-Resistant Epilepsy with Partial-Onset Seizures Receiving DBS Therapy.
DUBLIN - May 1, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval for Medtronic'
-
Apr 9, 2018Data on Implant Approach, Blood Pressure Management, Length of Stay, and Quality of Life to be Featured During Congress.
DUBLIN - April 9, 2018 - Medtronic plc (NYSE: MDT) today announced a preview of notable clinical data on the HeartWare HVAD® System that will be presented at The International Society of Heart...
-
Feb 28, 2018The Programs Are Expected to Benefit up to 500,000 Patients in Northeast Pennsylvania and Reduce Cost of Care by $100 Million
LEHIGH VALLEY, Pa. and DUBLIN - February 28, 2018 - Today, Medtronic plc (NYSE: MDT), the global leader in medical technology, and Lehigh Valley Health Network (LVHN), an eight-hospital network...
-
Feb 26, 2018FDA Approved, Resolute Onyx 2.0 mm DES Technology Tackles Clinical Challenge of Treating Coronary Artery Disease in Previously Untreatable Patients
DUBLIN - February 26, 2018 - Designed specifically for small vessels, Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute...
-
Nov 13, 2017
DUBLIN - November 13, 2017 - Medtronic plc (NYSE: MDT) today announced several noteworthy presentations of clinical studies and symposia on aortic, peripheral, endoVenous, and vascular...